Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells $47,535.58 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,979 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58. Following the completion of the sale, the chief technology officer directly owned 194,729 shares in the company, valued at approximately $4,677,390.58. This represents a 1.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Performance

Shares of CBLL opened at $23.37 on Friday. The stock has a market capitalization of $896.94 million, a price-to-earnings ratio of -13.28 and a beta of 0.81. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33. The firm has a fifty day simple moving average of $20.00 and a 200 day simple moving average of $19.32. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The business had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. Research analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CBLL. Strs Ohio acquired a new stake in CeriBell in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd increased its position in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter worth approximately $33,000. CWM LLC raised its stake in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the last quarter.

Wall Street Analysts Forecast Growth

CBLL has been the topic of several analyst reports. BTIG Research upped their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group boosted their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and an average target price of $22.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.